Accessibility Tools

Skip to main content

Pain Management

FDA Approves A First-in-Class Option for Moderate-to-Severe Acute Pain
FDA News, Pain Management
February 2025, Vol 2, No 2
Officials with Vertex Pharmaceuticals Incorporated announced that the FDA has approved suzetrigine (Journavx), a first-in-class, oral, nonopioid, highly selective NaV1.8 pain signal inhibitor for the treatment of adults with moderate-to-severe acute pain. Read More ›
AXS-07 Approved for Acute Migraine Treatment
FDA News, Pain Management, Neurology
February 2025, Vol 2, No 2
Axsome Therapeutics, Inc., a biopharmaceutical company, has announced that the FDA has approved meloxicam and rizatriptan (Symbravo) for the acute treatment of migraine with or without aura in adults. Read More ›